COMPASS THERAPEUTICS, INC. (CMPX) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $2.91M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $2.91M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $2.91M |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 24.12M USD | Liabilities |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Amounts owed to suppliers | 2.91M USD | Accounts Payable, Current |
| Total deferred revenue | (m) | |
| Deferred revenue due within one year | (m) | |
| Deferred revenue due after one year | (m) | |
| Reported other obligations due within one year | (m) | |
| Reported other noncurrent obligations | (m) | |
| Deferred revenue included in other noncurrent obligations | (m) |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $9.63M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $2.91M | (m) | (m) | (m) | $24.12M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $906.00K | (m) | (m) | (m) | $18.70M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $1.58M | (m) | (m) | (m) | $22.80M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $3.10M | (m) | (m) | (m) | $21.65M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $2.60M | (m) | (m) | (m) | $23.49M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $1.58M | (m) | (m) | (m) | $21.17M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $2.25M | (m) | (m) | (m) | $15.17M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $960.00K | (m) | (m) | (m) | $10.75M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $1.19M | (m) | (m) | (m) | $9.51M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $854.00K | (m) | (m) | (m) | $4.08M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $4.09M | (m) | (m) | (m) | $8.34M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $2.31M | (m) | (m) | (m) | $9.99M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $724.00K | (m) | (m) | (m) | $10.89M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $1.13M | (m) | (m) | (m) | $12.71M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $3.38M | (m) | (m) | (m) | $18.01M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $2.76M | (m) | (m) | (m) | $11.72M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $6.53M | (m) | (m) | (m) | $13.33M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $257.00K | (m) | (m) | (m) | $12.07M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $867.00K | (m) | (m) | (m) | $13.68M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $868.00K | (m) | (m) | (m) | $11.01M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $559.00K | (m) | (m) | (m) | $12.00M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $1.06M | (m) | (m) | (m) | $14.73M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $1.06M | (m) | (m) | (m) | $11.97M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $854.00K | (m) | (m) | (m) | $13.40M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $1.58M | (m) | (m) | (m) | $17.20M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | $111.82K | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | $103.28K | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | $91.34K | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | $86.92K | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | $75.45K | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | $66.40K | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | $54.03K | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | $50.26K | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | $34.58K | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |